- Home
- ACCS vs ALGS Comparison
ACCS vs ALGS Comparison
Compare ACCS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | ALGS |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 40.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACCS | ALGS |
|---|---|---|
| Price | $7.86 | $6.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $14.00 | ★ $39.33 |
| AVG Volume (30 Days) | 6.5K | ★ 188.6K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $7.40 | $32.20 |
| Revenue Next Year | $8.75 | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.51 | $4.20 |
| 52 Week High | $13.35 | $13.69 |
Technical Indicators
Market Signals| Indicator | ACCS | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 40.80 |
| Support Level | $7.82 | N/A |
| Resistance Level | $9.16 | $8.03 |
| Average True Range (ATR) | 0.31 | 0.72 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 18.38 | 13.33 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.